Regulation - Alexza Pharmaceutical

Filter

Current filters:

Alexza Pharmaceutical

Popular Filters

Positive EU regulatory news for Alexza and Ferrer, but not Gentium

22-02-2013

USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) and Spanish partner Grupo Ferrer Internacional have received…

AdasuveAlexza PharmaceuticalBiotechnologydefibrotideEuropeFerrer InternacionalGentiumNephrology and HepatologyNeurologicalPharmaceuticalRegulation

Positive recommendations from EMA's CHMP for Selincro, Adasuve and Perjeta

17-12-2012

Last week's deliberations of the European Medicines Agency's Committee for Medicinal Products for Human…

AdasuveAlexza PharmaceuticalBiotechnologyEuropeFerrer InternacionalLundbeckNeurologicalOncologyPerjetaPharmaceuticalRegulationRocheSelincro

FDA sets PDUFA date for Alexza's resubmission for Adasuve

08-07-2012

Following two earlier rejections, the US Food and Drug Administration has now accepted Alexza Pharmaceuticals…

AdasuveAlexza PharmaceuticalFerrer InternacionalNeurologicalNorth AmericaPharmaceuticalRegulation

Alexza rockets on re-submission of Adasuve NDA

25-06-2012

USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) saw its shares soar 44.9% to close at $3.97 on Friday,…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies

07-05-2012

California, USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) revealed last week that it has received another…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

PDUFA goal date for Alexza’s Adasuve extended, as Public Citizen says drug should not be approved

25-01-2012

US drug firm Alexza Pharmaceuticals (Nasdaq: ALXA) says that the US Food and Drug Administration will…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

Back to top